

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE SENATE

04 MAR 23 AM 11:22

**LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>Pharmaceutical Care Management Association</b>			
2. Address <input checked="" type="checkbox"/> Check if different than previously reported <b>601 Pennsylvania Avenue, NW suite 740, Washington, DC 20004</b>			
3. Principal Place of Business (if different from line 2) City: _____ State/zip (or Country) _____			
4. Contact Name <b>Brenda Palmer</b>	Telephone <b>(202) 207-3606</b>	E-mail (optional) <b>bpalmer@pcmanet.org</b>	5. Senate ID # <b>31348-12</b>
7. Client Name <b>self</b>	<input checked="" type="checkbox"/> Self		6. House ID # <b>34004000</b>

**TYPE OF REPORT** 8. Year 2003 Midyear (January 1-June 30) ☐ OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇨ Termination Date \_\_\_\_\_

11. No Lobbying Act

**INCOME OR EXPENSES** - Complete Either Line 12 OR Line 13**12. Lobbying Firms**

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000 ☐

\$10,000 or more ☐ ⇨ \$ \_\_\_\_\_  
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

**13. Organizations**


**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000 ☐

\$10,000 or more ☒ ⇨ \$ 280,000.00  
Expenses (nearest \$20,000)

**14. REPORTING METHOD.** Check box to indicate expense accounting method. See instructions for description of option:

- ☐ **Method A.** Reporting amounts using LDA definitions c
- ☐ **Method B.** Reporting amounts under section 6033(b)(8) Internal Revenue Code
- ☒ **Method C.** Reporting amounts under section 162(e) of Internal Revenue Code

Signature  Date **February 13, 2004**

Printed Name and Title Mark A. Merritt, President & CEO

LD-2 (REV. 4/03)

PAGE 1 of —

Registrant Name Pharmaceutical Care Management Association Client Name self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

HR-1, S-1, Medicare Prescription Drug, Improvement & Modernization Act of 2003, Title 1 & Title 2, all provisions relating to prescription drug benefits.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

United States House of Representatives  
United States Senate  
Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ellen Jenkins	
Tim Brogan	
Barbara Levy	
Greg Johnson	
Rebecca Gold	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature



Date 2/13/04

Printed Name and Title Mark Merritt, President & CEO

Form LD-2 (Rec. 4/03)

Page \_\_\_\_\_ of \_\_\_\_\_

Registrant Name Pharmaceutical Care Management Associa Client Name self

### Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

### LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

LaVarne Burton  
Sharon Canner

### ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

### AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

### FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Owns perce client

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client affiliated organization



Signature \_\_\_\_\_

Printed Name and Title Mark Merritt, President & CEO

Form LD-2 (Rev. 4/03)

Page \_\_\_\_\_ of